Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. - Wikidata - awgldk - TriplyDB

Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.

Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.

http://www.wikidata.org/entity/Q34430456

about

Modulation of the human glucuronosyltransferase UGT1A pathway by splice isoform polypeptides is mediated through protein-protein interactions Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034 Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir.Determination of metabolic profile of anti-malarial trioxane CDRI 99/411 in rat liver microsomes using HPLC.Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes.Inhibition of human cytochromes P450 by components of Ginkgo biloba.Bench to bedside: Pharmacogenomics, adverse drug interactions, and the cytochrome P450 system.Differential metabolism of alprazolam by liver and brain cytochrome (P4503A) to pharmacologically active metabolite.Cytochrome P450 induction properties of food and herbal-derived compounds using a novel multiplex RT-qPCR in vitro assay, a drug-food interaction prediction tool Interactions of herbs with cytochrome P450.18F-Mefway PET imaging of serotonin 1A receptors in humans: a comparison with 18F-FCWAY Influence of ketoconazole on azimilide pharmacokinetics in healthy subjects.Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics.Food-drug interactions via human cytochrome P450 3A (CYP3A).Depression, antidepressants and suicidality: a critical appraisal.New technologies and screening strategies for hepatotoxicity: use of in vitro models.DNA methylation mediates the effect of maternal smoking during pregnancy on birthweight of the offspring.The road map to oral bioavailability: an industrial perspective.Cell-based models to study hepatic drug metabolism and enzyme induction in humans.Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures?Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.Role of biotransformation in 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats.Treatment of acute tacrolimus toxicity with phenytoin in solid organ transplant recipients Drugs as CYP3A probes, inducers, and inhibitors.Fukinolic acid derivatives and triterpene glycosides from black cohosh inhibit CYP isozymes, but are not cytotoxic to Hep-G2 cells in vitro.Concurrent administration of sirolimus and voriconazole: a pilot study assessing safety and approaches to appropriate management.Interspecies considerations in the evaluation of human food safety for veterinary drugs.Management of drug and food interactions with azole antifungal agents in transplant recipients.Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro.In vitro approaches to studying the metabolism of new psychoactive compounds.Current understanding of drug disposition in kidney disease.PRISM, a generic large scale proteomic investigation strategy for mammals.Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective.Development of a miniaturized stimulation device for electrical stimulation of cells.Managing the Risk of CYP3A Induction in Drug Development: A Strategic Approach.Mechanisms and Consequences of Drug-Drug Interactions.Nano-sized cytochrome P450 3A4 inhibitors to block hepatic metabolism of docetaxel.Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.

P2860

Q24337041-EDFC01E9-3258-4C53-AEF5-EAFE6AF518E7 Q27489828-59048445-C680-4889-8A5D-825B30D871FC Q28261185-A3AEB14E-14AF-4FF7-A5D3-5BFC9BB26A4B Q33148910-08638F06-67B5-4570-871C-947B5D47750B Q33186873-337CC662-4467-4C1B-A0F3-F23174C7C607 Q33876677-437155FB-5A94-4A73-87A3-129F1A8303CD Q34224925-AFFECC16-8F2C-4C5B-AA43-63550163A0A0 Q34337497-D7F8B83B-F1CF-45FA-9C97-C078F745C141 Q34466778-87EFE4A0-8955-4CAD-B7D6-ED71675E73A3 Q34526540-E3D1DEF0-861F-4EB8-86CC-02420B02EB5C Q34542725-2026EF79-9169-438A-AFB9-5BB4BAF15A32 Q35085032-3CFA9FF3-AEE6-4004-9A9B-70F6E0FFAF05 Q35241015-B726CF5D-0919-42BC-B321-2FFFBB57C032 Q35826541-5E0CE161-07F9-4011-9036-BFEB1451D4A8 Q35827223-B7582E8C-A881-4271-9D3C-60E4E48DE269 Q36016526-43747518-3284-45EC-87DB-826307419BC9 Q36028253-86F697F1-7110-422B-B5DC-99E8527F1600 Q36086407-F4BF08BA-C317-483F-8ACC-3783D87F0546 Q36107685-1BEAFBF2-D053-4E80-8345-D40D8E2613BF Q36543116-D657A4FD-0813-44F1-90F7-ABC7E440B1EC Q36572634-2969482A-199E-42FF-AF1D-D3B5C6F1787D Q36628026-27033B70-C428-42E2-AE15-907295B929A1 Q36662912-6DD0FF09-BE2E-435D-94DA-4656F9594C8F Q36943606-D174CCA8-FE7C-46EF-89C0-8C23B186A678 Q36969224-45A50300-3B6C-4AB1-AAA6-1DFC2FEE5792 Q37023996-9484E5CF-2206-4BBC-87E5-B5B06FD4B06F Q37144642-7640C435-CC46-43C5-A13C-AB0A49B3202C Q37173189-1B9218E3-2B35-425E-9A2A-1F83F0031A03 Q37361815-BFF6C617-2C85-4879-98D3-7A0F61B30C48 Q37775009-576836AD-C39C-4493-8490-D75080A73547 Q37780212-5A4A9455-613E-4A15-8E88-FEEF077C94C0 Q37889234-B7C53C13-428D-4827-8F04-CB590AE01F88 Q37974644-C3566872-A43F-4D9E-BDF0-E13335EC67F9 Q38522885-BA2ABB34-8AA0-4B62-9624-288B5FD8BE69 Q38800092-912C1550-624A-4A5B-AD3C-04F7CDA61C6C Q38838041-DC09DD84-0B46-471E-9832-6E036BB14F9A Q39253133-CC00099C-AA33-4E0E-A93F-0F52086A3072 Q40306549-20DAE503-4087-4A2B-8FE1-98BF256A8E0C Q41283476-14B06DDC-6EC5-4C3F-845D-D036F2A73C0E Q42596957-7F6D2D59-3317-4A68-A076-5633E8B4BB1F

P2860

Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.

http://www.wikidata.org/entity/Q34430456

description

2001 nî lūn-bûn

@nan

2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Human drug metabolism and the ...... relevance of in vitro models.

@ast

Human drug metabolism and the ...... relevance of in vitro models.

@en

Human drug metabolism and the ...... relevance of in vitro models.

@nl

type

label

Human drug metabolism and the ...... relevance of in vitro models.

@ast

Human drug metabolism and the ...... relevance of in vitro models.

@en

Human drug metabolism and the ...... relevance of in vitro models.

@nl

prefLabel

Human drug metabolism and the ...... relevance of in vitro models.

@ast

Human drug metabolism and the ...... relevance of in vitro models.

@en

Human drug metabolism and the ...... relevance of in vitro models.

@nl

P1433

Q34430456-D46A6AE1-A848-4586-81E1-82A20D01EFAD

P1476

Q34430456-B72C44E4-DF39-444F-B45A-413DC6E94C1C

P2093

Q34430456-6389ABC2-9185-463F-8E4A-B322A12FE245

Q34430456-6FE2C93B-1976-4604-9A10-7F3034B14798

Q34430456-DB5CC16D-A7D4-4CCB-B1CB-06D32F6AEA0D

P2860

Q34430456-0151DF6E-A4D3-4A50-B7A2-A9C0D4897C6F

Q34430456-0AA3ADAC-5FF8-41A5-BECB-4668E3D0C116

Q34430456-0B39E6E9-584C-4857-909D-A2D93BD905C2

Q34430456-0B820952-4CE7-46CE-9CB7-A0D0558B80A0

Q34430456-1085DBA9-A2D4-48ED-96FB-44A86786F8E8

Q34430456-13A3D0B7-1930-4C8B-9427-5606B7B9716C

Q34430456-148A15A7-126B-4C41-A0AE-EBEE42A01AA7

Q34430456-1A4E3A67-104F-4795-86BB-4AE7EDBB6EF0

Q34430456-1D681AA9-824B-4F05-8684-E248DEB5C998

Q34430456-2222B833-3982-497D-9C94-90C5FEB3B0D7

P304

Q34430456-CF58EB54-4FDD-47B6-99C6-63BA80BBA2C7

P31

Q34430456-D13C7956-E694-45CA-8C47-C2D2C7152AEB

P356

Q34430456-ACB64532-A93C-4C44-A8CC-23B2F2D68D46

P433

Q34430456-3B8F2E39-A263-4DAD-9CF4-D6FEC226374C

P478

Q34430456-7D3462D2-2B7E-4132-9671-A38FE191464C

P577

Q34430456-A0CE8A8C-C3CA-4778-908A-D6AF0C20F3B1

P698

Q34430456-EA1237DF-4E57-4207-A1F8-4DA460A04AD9

P356

00912700122012724

P1433

The Journal of Clinical Pharmacology

P1476

Human drug metabolism and the ...... relevance of in vitro models.

@en

P2093

Greenblatt DJ

http://www.w3.org/2001/XMLSchema#string

Venkatakrishnan K

http://www.w3.org/2001/XMLSchema#string

Von Moltke LL

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans

Alternative splicing in the human cytochrome P450IIB6 gene generates a high level of aberrant messages

St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene

Flavin-containing monooxygenase mediated metabolism of psychoactive drugs by human brain microsomes

Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51

Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations

O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants

Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine.

P304

1149-1179

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/00912700122012724

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P577

2001-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11697750

http://www.w3.org/2001/XMLSchema#string